Skip to main content

ADRIATIC trial: a new beginning for the treatment of LS-SCLC

Intervista a David R. Spigel By 2 Giugno 2024No Comments
Congressi

Consolidation durvalumab will become the new standard of care for patients with LS-SCLC who have not progressed after cCRT? We met David R. Spigel (Chief scientific officer – Sarah Cannon Research Institute, Nashville) at the ASCO congress 2024 in Chicago and he explained us the importance of the data of the ADRIATIC trial.